UNSPSC 51283601: Rifampicin or rifampin

This classification denotes a rna polymerase inhibitor and antitubercular agent with the molecular formula C43H58N4O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJT6J7R4TR, chemically known as 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(n-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2h)-dione 21-acetate but generally known as rifampicin, which bears US NIH Compound Identifier 5381226.

UNSPSC 51283601 Rifampicin or rifampin is a Commodity code that nominally designates a specific tuberculosis antibiotic, but the recent state and local procurement activity posted under it does not involve rifampicin or rifampin purchases. The Illinois Department of Public Health's August 2026 piggyback pharmaceutical warehouse order through the MMCAP Infuse consortium and Seminole County, Florida's June 2026 naloxone and drug deactivation systems procurement both use different drug codes and products entirely. The code shows little relevant recent activity aligned with its stated scope, and the two opportunities on record are unrelated to each other and to rifampicin supply.

The geographic activity that does appear is confined to Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 contract over three years to Chartwell Rx LLC for doxycycline and ciprofloxacin tablets through an Invitation for Bid process; Seminole County issued an IFB for naloxone and drug deactivation systems with a July 26, 2023 response deadline (a past date). Neither opportunity involves rifampicin procurement. Business development professionals evaluating this code should verify the UNSPSC classification used in their target RFQ or RFP notice, as the current postings suggest systematic miscoding or administrative error rather than active demand for rifampicin under this commodity designation.